5 Healthcare Stocks On Fire This Week Five healthcare stocks have emerged as standout performers, posting remarkable week-on-week momentum gains according to the latest Benzinga Edge Ranking report. Benzinga · Aug 21, 2025
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? Shares of Evoke Pharma Inc (NASDAQ:EVOK) are trading sharply higher Wednesday morning after the specialty pharmaceutical company announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its lead product, GIMOTI. Benzinga · Jul 9, 2025
Evoke Pharma: Q1 Earnings Insights Evoke Pharma (NASDAQ:EVOK) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evoke Pharma missed estimated earnings by 75.0%, reporting an EPS of $-0.07 versus an estimate of $-0.04. Benzinga · May 10, 2022
Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ:EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults. Evoke now has exclusive marketing rights over three (3) years from the original date of approval under the Hatch-Waxman Act to protect the product from… Benzinga · Apr 26, 2022
Evoke Pharma Earnings Perspective: Return On Capital Employed According to Benzinga Pro data, during Q4, Evoke Pharma (NASDAQ:EVOK) posted sales of $360.57 thousand. Earnings were up 15.08%, but Evoke Pharma still reported an overall loss of $1.67 million. Benzinga · Mar 11, 2022
Recap: Evoke Pharma Q4 Earnings Evoke Pharma (NASDAQ:EVOK) reported its Q4 earnings results on Tuesday, March 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Benzinga · Mar 8, 2022
Evoke Pharma Earnings Preview Evoke Pharma (NASDAQ:EVOK) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement. Analysts estimate that Evoke Pharma will report an earnings per share (EPS) of $-0.08. Benzinga · Mar 7, 2022